Mitoxantrone, etoposide and intermediate-dose ara-c (MEC) for the treatment of acute myelogenous leukemia (AML)

S. Amadori, A. Spadea, M. C. Petti, P. Fazi, G. Meloni, A. P. Iori, A. Picardi, M. Rolla, F. Mandelli

Research output: Contribution to journalArticle

Original languageEnglish
Pages (from-to)69
Number of pages1
JournalLeukemia and Lymphoma
Volume7
Issue numberS2
DOIs
Publication statusPublished - 1992

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Amadori, S., Spadea, A., Petti, M. C., Fazi, P., Meloni, G., Iori, A. P., Picardi, A., Rolla, M., & Mandelli, F. (1992). Mitoxantrone, etoposide and intermediate-dose ara-c (MEC) for the treatment of acute myelogenous leukemia (AML). Leukemia and Lymphoma, 7(S2), 69. https://doi.org/10.3109/10428199209058667